Documentation Centre

August 22, 2008
Genetic screening of the LPL gene in hypertriglyceridaemic patients. Atherosclerosis 2008;199:187-92
Wright WT, Young IS, Nicholls DP, Graham CA.

Description of this Publication

Lipoprotein lipase (LPL) is one of the most important rate-limiting enzymes of triglyceride-rich lipoprotein catabolism, and loss of LPL function often leads to hypertriglyceridemia and cardiovascular disease. In a Northern Irish population, Wright et al. carried out a complete sequence analysis of the LPL gene in 19 individuals with severe hypertriglyceridemia [triglyceride levels ≥14 mmol/l] and identified 42 sequence variants. Moreover, 8 of those subjects were characterized by functional variants such as p.D36N, p.R197H, p.N318S, and p.V340I. In a larger case-control population, the p.N318S variant was found to be closely associated with hypertriglyceridemia [13% of cases (triglycerides ≥5 mmol/l) had the AG genotype vs. 4% for controls (triglycerides <2 mmol/L)]. This report, along with many other published studies, supports the view that LPL is an important candidate gene for hypertriglyceridemia. The authors suggested that gene-environment studies should be conducted to evaluate the effect of alcohol intake, diabetes, or obesity on the relationship between LPL gene variants and hypertriglyceridemia.

Consult publication on external website

By clicking on this link, you will leave the INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK website

Key Words